Topical Ectoin Versus Topical Dexpanthenol for Managing Acute Radiodermatitis Associated With Breast Cancer Radiotherapy: A Randomized Double-Blind Study.

RCT

Nagwa E Abd Elazim, Sara M Awad, Maha S El-Naggar, Rania H Mohamed

RCTDermatitis : contact, atopic, occupational, drug2023n=25

vote to see if the hive agrees

Research Facts

Topical Ectoin Versus Topical Dexpanthenol for Managing Acute Radiodermatitis Associated With Breast Cancer Radiotherapy: A Randomized Double-Blind Study.

Nagwa E Abd Elazim, Sara M Awad, Maha S El-Naggar, Rania H Mohamed

RCT · Strong · 2023 · Dermatitis : contact, atopic, occupational, drug · n=25

Findings

In a head-to-head test of 50 breast cancer patients, ectoin 7% cream performed better than dexpanthenol 5% cream at preventing radiation burn severity. Ectoin users experienced noticeably less pain and itching by week 2, and reported better quality of life overall. Both creams successfully prevented the worst cases of radiation damage, but ectoin came out ahead.

Design: RCT

Sample: n=25

Evidence: Strong

Journal: Dermatitis : contact, atopic, occupational, drug

Methodology

Researchers split 50 patients into two groups—one using ectoin cream, one using dexpanthenol—twice daily during and two weeks after radiation therapy. They tracked radiodermatitis severity, symptoms, and skin-related quality of life weekly in a double-blind study (meaning neither patients nor researchers knew who got what).

Funded By

Funding not disclosed in abstract